Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Hypertrophic cardiomyopathy

- PMLiVE

FDA hands BMS and bluebird bio a priority review for ide-cel

Updated review accepted after refuse-to-file letter was issued in May

- PMLiVE

BMS eyes approval for second Opdivo combo in kidney cancer

Detailed results presented at ESMO 2020 virtual congress

- PMLiVE

American Medical Association calls for COVID-19 vaccine development transparency

Organisation asks FDA to provide transparent information on review plans

- PMLiVE

FDA grants emergency approval for blood plasma treatments for COVID-19

Emergency approval granted despite concerns from top US health officials

- PMLiVE

BMS pays $475m for Dragonfly’s IL-12 immunotherapy programme

Agreement will focus on development in oncology and haematology

- PMLiVE

BMS pledges $300m to tackle health inequity and improve diversity

Drugmaker announces a series of commitments to expand inclusion

- PMLiVE

Bristol-Myers Squibb’s revenues rise on Celgene acquisition

Sales of immunotherapy Opdivo decreased due to COVID-19 impact

- PMLiVE

BMS/bluebird bio resubmit FDA application for myeloma CAR-T

Novel CAR-T therapy targets heavily pre-treated myeloma

- PMLiVE

FDA fast-tracks Pfizer/BioNTech’s COVID-19 vaccine candidates

Two investigational candidates granted accelerated review

- PMLiVE

BMS suspends new clinical trials as COVID-19 cases rise in US

Existing sites can continue to recruit new subjects

- PMLiVE

FDA green lights rapid coronavirus diagnostic test

Test can diagnose positive cases in approximately 45 minutes

- PMLiVE

FDA maintains COVID-19 therapeutics must meet a ‘gold standard’

Comes after President Trump called for expedited approval of potential treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links